MAPT and red-green color blindness: Future studies are needed to determine whether accumulation of tau pathology over time in CBD can be reliably measured with 18F-AV-1451 PET and to determine its usefulness as an additional diagnostic tool and as an outcome measure in trials evaluating new disease-modifying therapies against CBD.